TY - JOUR T1 - Clinical Outcomes of Hydrogel Spacer Injection Space OAR in Men Submitted to Hypofractionated Radiotherapy for Prostate Cancer JF - In Vivo JO - In Vivo SP - 3385 LP - 3389 DO - 10.21873/invivo.12637 VL - 35 IS - 6 AU - PIETRO PEPE AU - MARIA TAMBURO AU - MICHELE PENNISI AU - DARIO MARLETTA AU - FRANCESCO MARLETTA Y1 - 2021/11/01 UR - http://iv.iiarjournals.org/content/35/6/3385.abstract N2 - Background/Aim: To evaluate the clinical outcomes of men with prostate cancer (PCa) submitted to hydrogel spacer injection before hypofractionated radiotherapy (HRT). Patients and Methods: From April 2018 to April 2020, 32 patients with clinically localized PCa underwent hydrogel injection Space OAR before HRT to the prostate and seminal vesicle; the prescription dose was 60 Gy in 20 fractions, 5 days/week over 4 weeks. PSA levels, genitourinary (GU) and gastrointestinal (GI) toxicities, and sexual function were prospectively evaluated. Results: PSA levels at the median follow up of 15 months was 0.52 ng/ml; 28.1% vs. 78.1% patients had GI vs. GU Grade 0 acute toxicity and 93.7% vs. 0% had GI vs. GU Grade 0 late toxicity. Furthermore, 88.1% of patients kept pretreatment sexual potency. Conclusion: The use of the hydrogel Spacer OAR before HRT is useful for reducing acute and late GU and GI toxicities. ER -